FM401 / Future Medicine - LARVOL DELTA

GI Innovation-Future Medicine, joint research agreement for 4th generation metabolic immune anti-cancer drugs [Google translation] (Pharm News) - "GI Innovation...and Future Medicine...have developed a 4th generation metabolic immune anti-cancer drug. A joint research agreement (MOU) was signed on the 12th....GI Innovation is preparing to conduct clinical trials for a 4th generation dual fusion metabolic immunotherapy anti-cancer drug developed using GI-SMART platform technology, and Future Medicine has completed non-clinical trials for an A2AAR antagonist that is effective in co-administration with immune checkpoint inhibitors....GI Innovation CEO Lee Byeong-gun said, 'Through this agreement, we expect to see strong synergy in multi-faceted research, such as the combined administration of Future Medicine’s cancer immunotherapy candidate (FM401) and GI Innovation’s 4th generation metabolic immunotherapy'....Meanwhile, GI Innovation, a KOSDAQ-listed company, is actively conducting clinical trials in Korea and the U.S. for immune anti-cancer drugs GI-101...in addition to the 4th generation metabolic immune anti-cancer drugs."

Licensing / partnership • Oncology • Solid Tumor